PMC9452652_01
18F-FDG-PET/CT showed a right lower lobe malignant tumor (4.2 cmx3.3 cmx4.8 cm, SUVmax 9.6) with multiple right lung metastases and metastatic right pleural effusion.
fimmu-13-939873-g001.jpg
PMC9452652_01_fimmu-13-939873-g001.jpg
f1
Auxiliary examinations of whole-body PET/CT showed right lower lobe malignant tumor (4.2 cmx3.3 cmx4.8 cm, SUVmax 9.6, see  Figure 1 ) with multiple right lung metastases, right pleural metastasis, right pleural effusion; longitudinal diaphragm and bilateral hilar lymph node metastasis; multiple bone metastases all over the body, pathological fracture of the 10th posterior rib on the right side; low-density shadow of the left frontal lobe on the head, no abnormal radioactive uptake.
Pleural effusion sediment was confirmed to be adenocarcinoma. (hematoxylin-eosin stain, original magnification x 100).
fimmu-13-939873-g002.jpg
PMC9452652_01_fimmu-13-939873-g002.jpg
f2
Combined with clinical history and immunohistochemistry, the source was lung adenocarcinoma (see  Figure 2 ). Common mutation gene detection received a negative result.
The appearance of inflammatory changes and "mulberry-like" reactive cutaneous capillary endothelial proliferation on the patient's left breast skin.
fimmu-13-939873-g003.jpg
PMC9452652_01_fimmu-13-939873-g003.jpg
f3
Physical examination revealed enlargement of the left breast with pain, swelling, erythema, and warmth (see  Figure 3 ).
Breast ultrasound showed inflammatory changes in the left breast (the arrow points).
fimmu-13-939873-g004.jpg
PMC9452652_01_fimmu-13-939873-g004.jpg
f4
The ultrasound showed inflammatory changes with typical "finger-like" tubular formations emerging from hypoechoic areas in the left breast, no obvious effusion, and a poor blood flow signal (see  Figure 4  where the arrow points).
The timeline of different treatments for the patient's entire treatment progression.
fimmu-13-939873-g005.jpg
PMC9452652_01_fimmu-13-939873-g005.jpg
f5
Then, the symptoms of pain, swelling, erythema, and warmth of the breast gradually subsided according to the patient's feedback after giving up the fourth session of camrelizumab (the timeline of different treatments for the patient's entire treatment progression see  Figure 5 ).